Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US8618115B2 · kind B2 · utility
24Cited by
46References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 25, 2006 |
| Grant date | Dec 31, 2013 |
| Priority date | — |
| Expiry date | Aug 17, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.